in the past decade , interferon , the first of a new class of biologic response modifiers , has undergone extensive phase i and ii clinical evaluation in a broad spectrum of cancers , including hematologic malignancies , lymphomas , and solid tumors .
C0006826
cancers
C0024299
lymphomas